logo
Plus   Neg
Share
Email

EVOTEC, Indivumed Reach First Milestone In Joint Collaboration

Evotec SE (EVTCY.PK,EVOTF.PK), a German drug discovery and development company, and Indivumed GmbH announced Monday the reaching of first milestone in their joint collaboration to identify new therapeutic targets for the treatment of colorectal cancer.

Under the collaboration deal terms, Evotec received full access to the colorectal cancer or CRC multi-omics data of IndivuType. The milestone of selecting three novel drug targets was achieved in less than three months.

IndivuType is a business unit of Indivumed that offers true multi-omics database for individualised cancer therapy.

The companies noted that the first set of identified targets will now be progressed towards first-in-class therapeutics for the treatment of CRC using Evotec's multimodality drug discovery and development platforms.

Four additional candidate targets identified by Indivumed's bioinformatic and analytics will also enter the joint development programme.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Pfizer said Friday it reached a multi-year deal with Gilead Sciences to manufacture and supply Gilead's investigational antiviral remdesivir for COVID-19 patients. Ferring Pharmaceuticals US is recalling various nasal sprays citing superpotency or amounts of desmopressin higher than specified, the U.S. Food and Drug Administration announced in a statement. The recall involves all lots on the market of DDAVP Nasal Spray 10 mcg/0.1mL, Desmopressin Acetate Nasal Spray 10 mcg/0.1mL, and STIMATE Nasal Spray 1.5 mg/mL. U.S. President Donald Trump has issued executive orders to ban Chinese mobile application TikTok as well as WeChat, citing a threat to national security and its economy. China's ByteDance Ltd. owns TikTok, a video-sharing mobile app, while Tencent Holdings Ltd. owns WeChat, a messaging, social media, and electronic payment app.
RELATED NEWS
Follow RTT